• Home
  • Get a Doctor Appointment
    • Speed Up Your First Visit to Dr Gary Brewton
  • Meet Dr. Brewton
    • Take Control over Your Healthcare
    • Award-Winning Medical Care
    • The Health Insurance Plans You Trust
    • Mobile Technology Spoken Here
  • News
    • Wellness: Healthy Living Houston
    • Vaccinations
    • HIV Treatment
    • PrEP
    • Houston Museum District
  • Hours and Location Map
  • Contact Us
  • Patient Health Portal
    • Login to Our Patient Health Portal
    • Schedule Appointment
    • Change Appointment
    • Access Health Records
    • Access Lab Tests
    • Prescription Refills
    • Pre-Register as a New Patient
    • Ask Dr. Gary Brewton
    • Forgot your Password?
    • Login Help
    • Request for a Referral

Decoy Protein Foils HIV Virus in Monkey Study

Posted by Dr. Gary Brewton, MD on
 February 28, 2015
  · No Comments

Scientists from The Scripps Research Institute (TSRI) have presented a paper in the journal Nature, titled AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges, which outlines a novel approach to treating the HIV virus that causes AIDS.

The new approach has protected four laboratory monkeys over a year-long period from repeated exposure to an HIV variant used in lab tests called SHIV.

How does it work? The new treatment tricks the HIV virus into beginning viral replication with a custom decoy protein that is designed to mimic CD4 lymphocytes (a type of white blood cell, commonly called T cells) that are produced by the immune system to fight infections.

What normally happens in HIV viral replication is the virus attaches to a receptor on the surface of the CD4 cell, this in turn exposes a second receptor, the CCR5 receptor. Once the HIV virus successfully attaches itself to both the CD4 and CCR4 receptors it undergoes a shape change that allows it to inject its RNA into the cell.

Once its RNA is injected into the white blood cell, the cell essentially becomes a factory for rapidly reproducing more and more HIV virus. If not controlled, the viral replication leads to progressive destruction of the immune system that eventually results in Acquired Immune Deficiency or AIDS.

The image shows the part of HIV – shown in beige – that attaches to two receptors, CD4 and CCR5. Scripps Research Institute scientists and colleagues developed a drug candidate that binds both sites simultaneously. The drug includes part of CD4 (red), connected to a mimic of CCR5 (green). These parts are connected by a conserved piece of an antibody (gray). Because the inhibitor binds both sites simultaneously, it binds tightly and triggers the virus to change its shape, blocking HIV-1 more effectively than any currently available antibody therapy.

The image shows the part of HIV – shown in beige – that attaches to two receptors, CD4 and CCR5. Scripps Research Institute scientists and colleagues developed a drug candidate that binds both sites simultaneously. The drug includes part of CD4 (red), connected to a mimic of CCR5 (green). These parts are connected by a conserved piece of an antibody (gray). Because the inhibitor binds both sites simultaneously, it binds tightly and triggers the virus to change its shape, blocking HIV-1 more effectively than any currently available antibody therapy.

Interrupting this HIV replication has proven difficult. Part of the problem is that there are not one but three major strains of HIV: the main family, known as HIV-1, which is responsible for the majority human cases of the disease; HIV-2 and finally SIV (Simian Immunodeficiency Virus) which affects monkeys.

In turn, each of these different strains have their individual variations caused by genetic mutations. Because the HIV virus mutates rapidly, small mutations in the receptor sites have made it difficult to make a vaccine or find a universal antiviral treatment that addresses all the HIV strains and corresponding genetic variations.

That’s one of the reasons that the monkey study conducted by scientists at The Scripps Research Institute, along with researchers from Harvard, Princeton, Rockefeller University, the University of Southern California and the Pasteur Institute in France is a potential breakthrough. Their novel approach of using a decoy protein, seems to be potentially effective against all different HIV strains.

Michael Farzan is a professor at the Florida campus of The Scripps Research Institute.

Michael Farzan is a professor at the Florida campus of The Scripps Research Institute.

“Our compound is the broadest and most potent entry inhibitor described so far,” said TSRI Professor Michael Farzan, who led the research effort. “Unlike antibodies, which fail to neutralize a large fraction of HIV-1 strains, our protein has been effective against all strains tested, raising the possibility it could offer an effective HIV vaccine alternative.”

The decoy protein binds to two locations on the HIV virus at the same time. This triggers the HIV virus to begin replication, but unlike normal cells the unique Y shape of the decoy protein doesn’t allow the HIV virus sufficient contact area to do any damage.

Unlike normal HIV treatments, “when antibodies try to mimic the receptor, they touch a lot of other parts of the viral envelope that HIV can change with ease,” said TSRI Research Associate Matthew Gardner, the first author of the study along with Lisa M. Kattenhorn of Harvard Medical School. “We’ve developed a direct mimic of the receptors without providing many avenues that the virus can use to escape, so we catch every virus thus far.”

“This is the culmination of more than a decade’s worth of work on the biochemistry of how HIV enters cells,” Farzan said. “When we did our original work on CCR5, people thought it was interesting, but no one saw the therapeutic potential. That potential is starting to be realized.”

The next step in evaluating this approach is to test whether the decoy protein can stop the virus from replicating in monkeys already infected with SHIV. If successful, it would represent a therapeutic treatment of HIV in the animal model.

If that proves successful, Dr. Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases says the testing will move from the animal model to testing in humans.

 

Categories : 2015-02 February Newsletter, HIV treatment, Newsletter
← Next Post
Previous Post →

Search our Website

Find News by Topic

Browse Recent News

  • MATCH fires up a cultural transformation in Midtown Houston
  • Lipids and Cholesterol Patient Guide
  • Heart Disease Patient Guide
  • ZIKA Patient Guide
  • Deciding What We Want at the End of Life
  • 21st Annual International AIDS Conference in Durban, South Africa
  • How to protect yourself from the emerging threat of Zika Virus
  • Scientists research techniques for eliminating HIV infection in cells using CRISPR-Cas9 Genomic Editing Techniques
  • Truvada (PrEP) can help prevent HIV infection. Contact Dr. Gary Brewton today.
  • Out and About in the Houston Region: Dickens on the Strand in Galveston
  • The American Academy of HIV Medicine has re-certified Dr. Gary Brewton as an HIV Specialist
  • Dr. Gary Brewton receives top level Bridges to Excellence Diabetes Care Recognition
  • It happened on Caroline Street: a Guided Tour of Houston’s Museum District
  • Human Papillomavirus (HPV) Vaccine now Recommended for Young Men
  • New Guidelines for When to Start Taking Cholesterol-Lowering Statin Drugs
  • New warnings about Motrin, Advil and Aleve stroke and heart attack risks.
  • Welcome the Heroes at Houston Pride
  • Is Chocolate the Answer to Good Health?
  • MERS: What you need to know about this new disease.
  • Healthy Living Houston: Sitting is the New Smoking?
  • Print out our Museum District Event Map for May – June 2015
  • How to be a Houston Art Car Parade Insider
  • Houston Museum District and Montrose Event Map
  • Get Out and Get Active: Discover Houston Heights and More
  • Try Our Roasted Eggplant Baba Ganoush
  • Decoy Protein Foils HIV Virus in Monkey Study
  • MyFitnessPal can help improve your Houston State of Health
  • It’s Time to Get your Pertussis (Whooping Cough) Vaccine
  • Big Changes Coming to Houston’s Museum District
  • What’s Happening in the Houston Museum District, The Montrose and Houston Midtown?
  • How to “Lose It” Over the Holidays: Weight Loss Apps
  • How to Set Up Your Medical ID in Your Apple iPhone or iPad

Doctor Brewton is your Board-Certified, Common Sense Community Doctor serving the Houston Midtown, Houston Montrose, Houston Museum District, Houston Heights and Houston Texas Med Center neighborhoods for over thirty years. Call us at (713) 529-9224 to make an appointment.

Do you work in downtown Houston, Houston Midtown or at the Texas Medical Center? Take the Houston Metro Red Line directly to our office. Exit Houston Museum District Station, located one block west of our office.


Dr Gary Brewton, MD, FACP
1213 Hermann Drive, Suite 845, Houston, Texas 77004-7027 | Telephone (713) 529-9224
Copyright © 1985 – 2019 All Rights Reserved